Journal article
Molecular comparison of interval and screen-detected breast cancers
Dane Cheasley, Na Li, Simone M Rowley, Kenneth Elder, G Bruce Mann, Sherene Loi, Peter Savas, David L Goode, Tanjina Kader, Magnus Zethoven, Tim Semple, Stephen B Fox, Jia-Min Pang, David Byrne, Lisa Devereux, Carolyn Nickson, Pietro Procopio, Grant Lee, Siobhan Hughes, Hugo Saunders Show all
JOURNAL OF PATHOLOGY | WILEY | Published : 2019
DOI: 10.1002/path.5251
Abstract
Breast cancer (BC) diagnosed after a negative mammogram but prior to the next screening episode is termed an 'interval BC' (IBC). Understanding the molecular differences between IBC and screen-detected BCs (SDBC) could improve mammographic screening and management options. Therefore, we assessed both germline and somatic genomic aberrations in a prospective cohort. Utilising the Lifepool cohort of >54 000 women attending mammographic screening programs, 930 BC cases with screening status were identified (726 SDBC and 204 IBC). Clinico-pathological and family history information were recorded. Germline and tumour DNA were collected where available and sequenced for BC predisposition and drive..
View full abstractRelated Projects (5)
Grants
Awarded by Victorian Cancer Agency
Awarded by National Breast Cancer Foundation
Awarded by NHMRC
Awarded by Cancer Australia
Funding Acknowledgements
The authors would like to acknowledge the Bioinformatics and Molecular Genomics Core Facilities of the Peter MacCallum Cancer Centre. This work would not have been possible without financial support by the Victorian Cancer Agency (ECSG15003, DC), the National Breast Cancer Foundation (IF-15-004 and CG-08-02, IGC), the NHMRC (APP1079329 SF) and Cancer Australia (1084963, IGC). The funders had no role in the design and execution of this study.